Biogen patent survives challenge by hedge fund manager Kyle Bass

NEW YORK, Sept 2 (Reuters) - In another setback for prominent hedge fund manager Kyle Bass and his campaign to eliminate some drug patents, the U.S. Patent and Trademark Office on Wednesday declined to hold a trial on the validity of a patent on Biogen Inc's multiple sclerosis drug Tecfidera.